StreetInsider.com News Articles

Zai Lab stock jumps on cancer drug data and $250m raise

Fri, 23 Oct 2026 10:00:11 -0400

Zai Lab stock climbed 7.2% in morning trading Friday to $23.62 following the release of clinical trial data for its cancer drug candidate and the announcement of a $250 million financing round.

The company shared Phase 1b trial results for zocilurtatug pelitecan, its DLL3-targeting antibody-drug conjugate. The trial showed an 81.8% confirmed objective response rate and an 81.9% six-month progression-free survival rate among 33 first-line extensive-stage small cell lung cancer patients treated at the recommended Phase 3 dose.

The data was presented ahead of the European Society for Medical Oncology Congress 2026 in Madrid. Zai Lab held an investor webcast at 8:00

Zai Lab's zoci shows 81.8% response rate in lung cancer trial

Fri, 23 Oct 2026 06:33:40 -0400

Zai Lab Limited (NASDAQ: ZLAB) released Phase 1b clinical trial data showing its antibody-drug conjugate zocilurtatug pelitecan (zoci) combined with atezolizumab achieved a confirmed objective response rate of 81.8% in patients with first-line extensive-stage small cell lung cancer (ES-SCLC), according to a company statement.

The data, presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, covers 33 patients treated at the recommended Phase 3 dose of 1.6 mg/kg. The six-month progression-free survival rate was 81.9%. Among 15 patients with at least six months of follow-up, median progression-free survival and median duration of response had not been reached

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Can

Fri, 23 Oct 2026 06:33:00 -0400

At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC
Among patients with at least six-months follow-up (n=15) treated at 1.6 mg/kg zoci plus atezolizumab, median progression-free survival and median duration of response were not yet reached after a median follow-up of 10 months
Zoci plus atezolizumab therapy was well-tolerated; Grade >3 AEs related to zoci occurred in 9.1% (3/33) of patients treated at 1.6mg/kg
Global, randomized Phase 3 study in 1L ES-SCLC expected to initiate by

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Can

Fri, 23 Oct 2026 06:33:00 -0400

At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC

Among patients with at least six-months follow-up (n=15) treated at 1.6 mg/kg zoci plus atezolizumab, median progression-free survival and median duration of response were not yet reached after a median follow-up of 10 months

Zoci plus atezolizumab therapy was well-tolerated; Grade >3 AEs related to zoci occurred in 9.1% (3/33) of patients treated at 1.6mg/kg

Global, randomized Phase 3 study in 1L ES-SCLC expected to initiate by

Form 8-K Zai Lab Ltd For: Oct 22

Fri, 23 Oct 2026 06:07:00 -0400
si-local-file:///var/storage/secattach/20261023/27224672.html

Zai Lab raises $250M in PIPE financing for ADC drug development

Thu, 22 Oct 2026 20:52:18 -0400

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has entered into a securities purchase agreement to sell 11,340,000 American Depositary Shares (ADSs) at $22.04 per ADS in a private investment in public equity (PIPE) financing, with gross proceeds expected to reach approximately $250 million before placement agent fees and other expenses.

The financing is led by TCGX and includes abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management LP, Wellington Management, and Woodline Partners LP. The transaction is expected to close on or about October 27, 2026,

Zai Lab Announces $250 Million Private Placement

Thu, 22 Oct 2026 20:52:00 -0400

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares (“ADSs”), each representing ten ordinary shares of the Company, to certain investors in a private investment in public equity (“PIPE”) financing. The purchase price of each ADS is $22.04. Gross proceeds from the PIPE financing are expected to be approximately $250 million, before deducting placement agent fees and other offering expenses. The PIPE financing is expected to close on or about

Zai Lab Announces $250 Million Private Placement

Thu, 22 Oct 2026 20:52:00 -0400

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares (“ADSs”), each representing ten ordinary shares of the Company, to certain investors in a private investment in public equity (“PIPE”) financing. The purchase price of each ADS is $22.04. Gross proceeds from the PIPE financing are expected to be approximately $250 million, before deducting placement agent fees and other offering expenses. The PIPE financing is expected to close on or about

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

Wed, 21 Oct 2026 07:30:00 -0400

- Company to host conference call and webcast on November 5, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2026 financial results and provide recent corporate updates on November 5, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Conference Call and Webcast Information
The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

Wed, 21 Oct 2026 07:30:00 -0400

- Company to host conference call and webcast on November 5, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2026 financial results and provide recent corporate updates on November 5, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Conference Call and Webcast Information
The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants

Zai Lab to share first ZL-1503 clinical data at ACAAI 2026

Wed, 14 Oct 2026 07:01:53 -0400

Zai Lab Limited (NASDAQ: ZLAB) announced it will present data from the first clinical trial of ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, AZ, running November 12-16, 2026.
The data, drawn from a Phase 1/1b first-in-human study in healthy volunteers (NCT07235384), will be presented as a poster on November 13, 2026. The presentation will include pharmacokinetic data from single-dose administration, pharmacodynamic data on atopic dermatitis-related biomarkers across a range of doses, and initial safety and immunogenicity findings.
ZL-1503 is designed to simultaneously block both IL-13 and IL-31

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Wed, 14 Oct 2026 07:00:00 -0400

- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting

- Previous non-clinical studies demonstrated the potential for ZL-1503 to provide rapid itch relief and reduce inflammation in atopic diseases

- Investor conference call and webcast to discuss data being presented at ACAAI and clinical trial plans scheduled for Friday, November 13 at 8:00 a.m. ET / 9:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company’s internally

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Wed, 14 Oct 2026 07:00:00 -0400

- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting

- Previous non-clinical studies demonstrated the potential for ZL-1503 to provide rapid itch relief and reduce inflammation in atopic diseases

- Investor conference call and webcast to discuss data being presented at ACAAI and clinical trial plans scheduled for Friday, November 13 at 8:00 a.m. ET / 9:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company’s internally

Zai Lab (ZLAB) Reiterated at Overweight by Cantor Fitzgerald

Tue, 06 Oct 2026 07:42:10 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $37 price target on Zai Lab (NASDAQ: ZLAB).
The analyst commented, "Shares have rallied since 2Q earnings, and the recent withdrawal of I-DXd (B7-H3 ADC; Merck) puts Zai’s first-in-class DLL3 ADC, zocilurtatug, in pole position to potentially become the first ADC approved in 2L ES-SCLC. More importantly, ESMO data from initial 1L SCLC cohorts of zoci + atezolizumab with or without carboplatin could de-risk the 1L path, which has proven challenging for other ADCs. We think a 70–80% ORR and ~7-month mPFS are largely priced in; mPFS >8 months may be

Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen Yajing

Mon, 05 Oct 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20261005/27149477.html

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Tue, 29 Sep 2026 07:00:00 -0400

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin

Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC

Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for Friday, October 23 at 8:00 a.m. ET / 8:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Tue, 29 Sep 2026 07:00:00 -0400

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin

Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC

Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for Friday, October 23 at 8:00 a.m. ET / 8:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for

Zai Lab (ZLAB) PT Raised to $36 at JPMorgan

Thu, 27 Aug 2026 08:33:56 -0400
JPMorgan analyst Anupam Rama raised the price target on Zai Lab (NASDAQ: ZLAB) to $36.00 (from $27.00) while maintaining a Overweight rating.

Form 144 Zai Lab Ltd Filed by: Smiley Joshua L

Thu, 20 Aug 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260820/26956450.html

Form 144 Zai Lab Ltd Filed by: Smiley Joshua L

Thu, 20 Aug 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260820/26956450.html

Form 144 Zai Lab Ltd Filed by: Smiley Joshua L

Thu, 20 Aug 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260820/26956450.html

Form 144 Zai Lab Ltd Filed by: Chen Yajing

Wed, 19 Aug 2026 13:51:00 -0400
si-local-file:///var/storage/secattach/20260819/26949395.html

Form 144 Zai Lab Ltd Filed by: Chen Yajing

Wed, 19 Aug 2026 13:51:00 -0400
si-local-file:///var/storage/secattach/20260819/26949395.html

Form 144 Zai Lab Ltd Filed by: Chen Yajing

Wed, 19 Aug 2026 13:51:00 -0400
si-local-file:///var/storage/secattach/20260819/26949395.html

Zai Lab and argenx report Phase 3 trial win for myositis drug

Mon, 17 Aug 2026 06:00:59 -0400

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.

The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).

In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement